読み込み中
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
前日終値
$52.125
+$0.085 · +0.16%
日中の時刻はETです。市場データは遅延する場合があります。
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
日中レンジ
現在 $52.125
52週レンジ
現在 $52.125
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
78
割安
センチメント
58
まちまち
リスク
37
中程度のリスク
モメンタム
62
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
日中レンジ
現在 $52.125
52週レンジ
現在 $52.125
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4.91億 USD | 2.33億 USD | 1.45億 USD | 1.09億 USD | 1.32億 USD |
| 売上原価 | 1033.9万 USD | 774.4万 USD | 1145万 USD | 442万 USD | 381.8万 USD |
| 粗利益 | 4.8億 USD | 2.25億 USD | 1.34億 USD | 1.05億 USD | 1.28億 USD |
| 研究開発 | 2.06億 USD | 2.83億 USD | 2.45億 USD | 2.27億 USD | 2.01億 USD |
| 販売・一般管理 | 3.37億 USD | 2.64億 USD | 2.66億 USD | 1.98億 USD | 1.26億 USD |
| 営業費用 | 5.43億 USD | 5.49億 USD | 5.22億 USD | 4.25億 USD | 3.27億 USD |
| 受取利息 | 1272.1万 USD | 1781.7万 USD | 2176.8万 USD | 627.6万 USD | 199.3万 USD |
| 支払利息 | 1074.8万 USD | 1118.2万 USD | 1133.4万 USD | 1101.4万 USD | 1968.2万 USD |
| 減価償却費と償却費 | 6074.3万 USD | 4355.5万 USD | 3853万 USD | 2071.9万 USD | 1274.6万 USD |
| 営業利益 | −6282.4万 USD | −3.24億 USD | −3.88億 USD | −3.2億 USD | −1.99億 USD |
| 純利益 | −2554.6万 USD | −3.22億 USD | −1.11億 USD | −2.78億 USD | −1.8億 USD |
会社概要が更新されました 2026年10月11日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$70.60
上昇余地（35.44%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.96億0.01%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM1.22億0.16%787.4億 USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1.18億1.19%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF7161.33万0.07%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO4294.89万0.31%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB3684.69万0.35%108.2億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO3406.23万0.19%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA2605.95万0.12%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
